Suppr超能文献

[重组人β干扰素与γ干扰素联合作用于裸鼠癌性腹膜炎实验模型的研究]

[Combined effect of human recombinant interferon-beta and interferon-gamma against an experimental model of peritonitis carcinomatosa in nude mice].

作者信息

Kondo H, Tanaka N, Naomoto Y, Orita K

出版信息

Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1836-40.

PMID:3109328
Abstract

The development of useful therapy for the peritonitis carcinomatosa of gastrointestinal cancer is an important theme in cancer therapy. We developed an experimental model of peritonitis carcinomatosa in nude mice transplanted intraperitoneally human colon cancer cells. In this study, we investigated combined effect of human recombinant interferon-beta (rIFN-beta) and recombinant interferon-gamma (rIFN-gamma) in vivo using this model. The result indicate that each rIFN-beta and rIFN-gamma showed a significant prolonged survival compared with the control group (mean survival days: 41.8 +/- 5.0 days). Furthermore, combined administration of rIFN-beta and rIFN-gamma showed a marked prolonged survival (mean survival days: 114.0 +/- 7.4 days) compared with rIFN-beta or rIFN-gamma alone. These results suggest that a combined treatment of rIFN-beta and rIFN-gamma may be useful against peritonitis carcinomatosa of gastrointestinal cancer.

摘要

开发针对胃肠道癌腹膜癌的有效治疗方法是癌症治疗中的一个重要课题。我们建立了一个在裸鼠体内腹腔移植人结肠癌细胞的腹膜癌实验模型。在本研究中,我们使用该模型研究了人重组干扰素-β(rIFN-β)和重组干扰素-γ(rIFN-γ)在体内的联合作用。结果表明,与对照组相比,rIFN-β和rIFN-γ各自均显著延长了生存期(平均生存期:41.8±5.0天)。此外,与单独使用rIFN-β或rIFN-γ相比,联合使用rIFN-β和rIFN-γ显著延长了生存期(平均生存期:114.0±7.4天)。这些结果表明,rIFN-β和rIFN-γ联合治疗可能对胃肠道癌腹膜癌有效。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验